Glucose-6-Phosphate

An ester of glucose with phosphoric acid, made in the course of glucose metabolism by mammalian and other cells. It is a normal constituent of resting muscle and probably is in constant equilibrium with fructose-6-phosphate. (Stedman, 26th ed)

Also Known As:

Networked: 413 relevant articles (2 outcomes, 16 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Mansfield, Brian C: 15 articles (11/2018 - 03/2002)
2.	Chou, Janice Y: 13 articles (11/2018 - 06/2008)
3.	Jun, Hyun Sik: 11 articles (04/2022 - 06/2008)
4.	Lee, Young Mok: 10 articles (04/2022 - 10/2010)
5.	Pan, Chi-Jiunn: 9 articles (11/2012 - 12/2002)
6.	Annabi, Borhane: 6 articles (05/2010 - 03/2006)
7.	Weinstein, David A: 5 articles (01/2021 - 05/2014)
8.	Chou, Janice Yang: 5 articles (11/2003 - 03/2002)
9.	Chou, J Y: 4 articles (02/2007 - 11/2000)
10.	Ciara, Elżbieta: 3 articles (05/2022 - 12/2021)

Related Diseases

1.	Hyperglycemia 04/01/2004 - "Consequently, whereas hyperglycemia had little effect on gluconeogenic flux to glucose 6-phosphate (G-6-P), net hepatic gluconeogenic flux was reduced because of increased hepatic glycolytic flux during hyperglycemia. " 10/01/1996 - "In fact, in response to hyperglycemia the "direct" pathway of hepatic glucose-6-phosphate (G-6-P) formation was approximately 40% lower with GlcN compared with saline infusion (37 +/- 3 vs. 63 +/- 3%; P < 0.001). " 01/01/1992 - "After hyperglycemia, hepatic glucose-6-phosphate concentrations were increased in both groups, whereas UDPglucose concentrations were reduced only in the control group. " 02/01/1992 - "The activity of glycogen synthase in muscle biopsies (fractional velocities [0.1 and 10 mM glucose 6-phosphate (G6P)]) decreased slightly during hyperglycemia (18 +/- 2 vs. 12 +/- 2%, P less than 0.05) and on the control day (26 +/- 4 vs. 20 +/- 3%, P less than 0.05). " 04/15/2003 - "Increased glucose cycling between glucose and glucose-6-phosphate is characteristic of insulin resistance and hyperglycemia seen with Type II diabetes. "
2.	Hypoglycemia (Reactive Hypoglycemia) 06/01/1994 - "Muscle glucose-6-phosphate concentrations rose during hypoglycemia by a twofold greater increment in NIDDM (P < 0.01). " 11/21/2003 - "A glucose-6-phosphate hydrolase, widely expressed outside the liver, can explain age-dependent resolution of hypoglycemia in glycogen storage disease type Ia." 09/01/1982 - "Deficiency of glucose-6-phosphatase in Type I glycogen storage disease (GSD) results in hypoglycemia and excessive accumulation of glucose-6-phosphate. " 02/23/2023 - "Glycogen Storage Disease type 1b (GSD1b) is a rare disease manifesting as hypoglycemia, recurrent infections and neutropenia, resulting from deleterious mutations in the SLC37A4 gene encoding the glucose-6-phosphate transporter. " 10/08/2021 - "The above data strongly imply that hepatic PKCβ deficiency causes hypoglycemia postprandially by promoting glucose phosphorylation via upregulating glucokinase and subsequently redirecting more glucose-6-phosphate to glycogen via activating GS. "
3.	Glycogen Storage Disease (Glycogenosis) 11/01/1980 - "The contradictory data obtained in studies of type 1b glycogenosis would be explained by an anomeric preference for the capture of glucose-6-phosphate by hepatic microsomes. " 05/19/2023 - "Glycogen storage disease type Ib (GSD1b) is due to a defect in the glucose-6-phosphate transporter (G6PT) of the endoplasmic reticulum, which is encoded by the SLC37A4 gene. " 04/28/2023 - "Identification of mutations that causes glucose-6-phosphate transporter defect in tunisian patients with glycogenosis type 1b." 05/01/2022 - "Glycogen storage disease type 1b (GSD 1b) is an inherited metabolic defect caused by biallelic mutations in the SLC37A4 gene encoding microsomal glucose-6-phosphate (G6P) transporter in the endoplasmic reticulum (ER) membrane. " 01/01/2021 - "Glycogen storage disease (GSD) type Ib is an autosomal recessive disease caused by defects of glucose-6-phosphate transporter (G6PT), encoded by the SLC37A4 gene. "
4.	Type 2 Diabetes Mellitus (MODY) 03/01/2005 - "Evolutionary chemistry approach toward finding novel inhibitors of the type 2 diabetes target glucose-6-phosphate translocase." 06/01/1994 - "Muscle glucose-6-phosphate concentrations rose during hypoglycemia by a twofold greater increment in NIDDM (P < 0.01). " 12/01/2021 - "Haplotypes of the genes (GCK and G6PC2) underlying the glucose/glucose-6-phosphate cycle are associated with pancreatic beta cell glucose sensitivity in patients with newly diagnosed type 2 diabetes from the VNDS study (VNDS 11)." 02/01/2011 - "Tissue-specific dysregulation of hexose-6-phosphate dehydrogenase and glucose-6-phosphate transporter production in db/db mice as a model of type 2 diabetes." 05/01/1996 - "We concluded that during fructose administration: 1) gluconeogenesis is increased, but EGP remains constant in NIDDM, obese non-diabetic, and lean individuals; 2) in lean individuals, both an increased glucagonaemia and an enhanced supply of gluconeogenic precursors are required to increase EGP; this increase in EGP occurs without changes in the relative proportion of glucose 6-phosphate production from fructose and from other sources (i.e. "
5.	Hypoxia (Hypoxemia) 05/01/2010 - "Novel roles in cell survival and metabolic adaptation to hypoxia have been ascribed to the microsomal glucose-6-phosphate translocase (G6PT). " 03/01/1991 - "Response to Anoxia in Rice and Wheat Seedlings: Changes in the pH of Intracellular Compartments, Glucose-6-Phosphate Level, and Metabolic Rate." 09/01/1977 - "Role of glucose-6-phosphate in cerebral dysfunction following hypoxia and hypotension." 05/01/2014 - "In this issue of Blood, Jun et al, through the study of neutrophils deficient in the glucose-6-phosphate transporter, describe a novel role for the peroxisome proliferator-activated receptor-γ (PPARG) pathway in the regulation of key neutrophil functions and link this to concomitant hypoxia-inducible factor (HIF) 1α stabilization." 03/01/2009 - "Given that MSCs can survive hypoxia and that the glucose-6-phosphate transporter (G6PT) provides metabolic control that contributes to MSC mobilization and survival, we investigated the effects of low oxygen (1.2% O(2)) exposure on G6PT gene expression. "

Related Drugs and Biologics

1.	Glucose (Dextrose)
2.	Glycogen
3.	Phosphates (Orthophosphate)
4.	Messenger RNA (mRNA)
5.	Biomarkers (Surrogate Marker)
6.	Triglycerides (Triacylglycerol)
7.	Glycogen Synthase (Synthase I)
8.	Isotopes
9.	Enzymes
10.	Lactic Acid (Lactate)

Related Therapies and Procedures

1.	Resuscitation
2.	Ovariectomy (Oophorectomy)
3.	Pancreaticoduodenectomy
4.	Lenses
5.	Induced Hyperthermia (Thermotherapy)